The Glycolytic Pathway as a Target for Novel Onco-Immunology Therapies in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal forms of human cancer, characterized by unrestrained progression, invasiveness and treatment resistance. To date, there are limited curative options, with surgical resection as the only effective strategy, hence the urgent need to disc...
Main Authors: | Claudia Curcio, Silvia Brugiapaglia, Sara Bulfamante, Laura Follia, Paola Cappello, Francesco Novelli |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/26/6/1642 |
Similar Items
-
Next Generation Immunotherapy for Pancreatic Cancer: DNA Vaccination is Seeking New Combo Partners
by: Paola Cappello, et al.
Published: (2018-02-01) -
Integrative Analysis of Novel Metabolic Subtypes in Pancreatic Cancer Fosters New Prognostic Biomarkers
by: Laura Follia, et al.
Published: (2019-02-01) -
An Immunological Glance on Pancreatic Ductal Adenocarcinoma
by: Michael Karl Melzer, et al.
Published: (2020-05-01) -
Targeting Glycolysis in Macrophages Confers Protection Against Pancreatic Ductal Adenocarcinoma
by: Hweixian Leong Penny, et al.
Published: (2021-06-01) -
PKM2: A Potential Regulator of Rheumatoid Arthritis via Glycolytic and Non-Glycolytic Pathways
by: Danyi Xu, et al.
Published: (2019-12-01)